



Huntingtons Disease: A Case Report

**Khushbu Meshram^{1*}, Tabbassum Sheikh¹, Pooja Kasturkar¹, Jaya Khandar¹,
Shital Sakharkar¹ and Prerana Sakharwade¹**

¹Sawangi Meghewardha Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Medical Sciences (Deemed to be University) Sawangi (Meghe) Wardha, Maharashtra, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i47B33093

Editor(s):

(1) Dr. Giuseppe Murdaca, University of Genoa, Italy.

Reviewers:

(1) Francesco Baudi, University of Catanzaro Magna Græcia, Italy.

(2) Mohamed Alshimy, Minufiya University, Egypt.

Complete Peer review History: <https://www.sdiarticle4.com/review-history/74007>

Case Study

Received 27 July 2021
Accepted 01 October 2021
Published 30 October 2021

ABSTRACT

Background: Huntington's disease (HD) is a genetic neurodegenerative illness characterized by progressive nerve cell degeneration in the brain, mainly in the basal ganglia. It often manifests itself between the ages of 30 and 40. The disease is including inherited genetic genes, which means that the affected person inherits the gene from a parent who also has the same genes. In populations of western European origin, the incidence of inherited genetic diseases is 3-10 per 1,00000. In India, it is far less common.

Case Presentation: This is a case of a 57 -year-old female schoolteacher who was brought to our institution with a trembling movement all over the body and imbalancing while walking. The clinical presentation of characteristics such as difficulty controlling his hands and fingers due to involuntary, uncontrolled motions is used to make the diagnosis He walked without a cane and seemed to be in good physical shape, yet when asked to sit, he slumps heavily into the chair. CT or MRI scans indicate lacunar ischemic foci in bilateral periventricular white matter. Mild cerebral and cerebellar atrophy was present. Complete blood testing were also carried out.

Conclusion: There are currently few therapies available. The emergence of treatment methods capable of directly targeting HTT, on the other hand, signals a new phase in HD research. There is now more than ever a serious possibility of modifying and preventing HD.

Keywords: Genetic disorders; hereditary; huntington disease; huntington chorea; neurodegenerative; case report.

1. INTRODUCTION

Huntington's disease is a hereditary nervous system disorder that produces uncontrolled choreiform movement and dementia. The disease affects around 1 in 10,000 men and women of all races in their forties. Everyone possesses the gene that causes Huntington's disease; however, only those who inherit the gene's expansion will develop the disease and pass it on to their descendants. Because Huntington disease is inherited by an autosomal dominant gene, any child of a parent with the condition has a 50% chance of acquiring it. "No treatments can alter the course of Huntington's disease" As a result, the emphasis is on improving quality of life with accessible medicines and supportive therapy [1].

1.1 Aim

The aim of the study reveals the patients history, prognosis, behavioral, mental, and motor abnormalities are all factors in its clinical and etiopathogenic presentation.

1.2 Presentation of Case

Following an inquiry, a 57 -year-old man was taken to Acharya Vinoba Bhave Rural Hospital Wardha on the 15th of March, with the main complaint of difficulties handling and grasping things at his employment as a teacher. Apathy and emotional outbursts were also reported as cognitive consequences.

1.3 Present Medical History

Following genetic testing, CAG repeat expansion in Huntington gene (HTT) also called IT-15 gene is determined by two separate PCR assays, – this assays determines the size of the triplet repeat. The patient had 15/41 CAG repeat determines the expanded allele shown in TP-PCR and denotes the full penetrance and diagnosis has been confirmed of Huntington's disease, where, A 57 -year-old female was brought to Acharya Vinoba Bhave Rural Hospital Wardha on the 15th of March, with the major complaint of difficulties handling and holding items at his employment as a teacher as trembling movement all over the body and imbalancing while walking. Apathy and emotional outbursts were also reported as

cognitive consequences. On admission, the patient talked with increased volume and pace.

1.4 Past Medical History

Two years ago, the patient notified his family doctor that he was feeling abnormally melancholy on most days and that he was no longer enjoying any happiness in her life. Family history: The patient was alright in the past 50 years before. Six months before the patient was diagnosed with Huntington's disease, her mother had a TIA (Transient Ischemic Attack). She has 2 son and 2 daughters which they are all married and doctor advised them to do the genetic test regarding Huntington's disease which 39 year old daughter has positive for the test. Doctor has advised the treatment on discharge Tab Revocon 25 mg 2 times a day and Tab- Sizodon 0.5 mg once a day and follow-up after 7 days.

2. ETIOLOGY

Huntington's disease is caused by an autosomal dominantly inherited CAG trinucleotide repeat expansion in the Huntington (HTT) gene on chromosome [2]. Expansion of an unstable polymorphic trinucleotide (CAG) repeat in axon 1 of the HTT gene or the IT 15 gene, which results in an expanded polyglutamine tract in the protein, is thought to induce a dominant gain of function, resulting in neuronal malfunction and neurodegeneration [3]. Symptoms are probable if it occurs 40 times or more. This alteration leads in a more lethal version of the huntingtin protein. It destroys particular brain cells as it accumulates in the brain.It weakens and finally destroys their function. Scientists also not sure how this happens [4].

2.1 Clinical Diagnosis

The clinical presentation of symptoms, a positive family history, and the presence of the genetic marker CAG repeats in HTT are used to make the diagnosis. CAG-Expanded allele and full penetrance. Before motor complaints emerge, CT scan or MRIs scans indicate symmetrical striatal atrophy.

2.2 Pathological Discussion

Huntington's disease is a chronic, progressive hereditary disorder defined by the early death of

cells in the striatum of the basal ganglia, a deep within the brain area crucial in movement control [5]. Cells are also lost in the cortex, which is associated with thinking, memory, perception, judgement, and action, as well as in the cerebellum, which is located at the top of the brain. The CAG repeat expansion is unstable and can lengthen during transmission from parents to offspring. Thus age can decrease the from one generation to the next this called as anticipation [6].

2.3 Physical Examination

The patient's hands and fingers exhibit uncontrolled, uncontrollable writhing and flexion/extension movements on both sides. He also has mild twitching of his ankles on both sides. With a little thoracic kyphosis, the posture is upright and symmetrical. Gait is characterized by bilateral symmetrical limb movement; cadence and speed were usual. Medical monitoring is required. Because there is no therapy that can stop or reverse the underlying condition, the emphasis is on enhancing quality of life via the use of affordable medications and supportive care. Tetrabenazine is the only medicine licenced by the Food and Drug Administration to treat the symptom of chorea (Xenazine Benzodiazepines and neuroleptic medications have also been found to help in chorea management [7]. Motor signals must be examined and analyzed on a continuous basis in order to achieve appropriate therapeutic medication levels. Akathisia (physical restlessness) in an overmedicated patient is dangerous since it might be mistaken for the illness's restless fretting and therefore

disregarded. Antiparkinson medicines, such as levodopa, may provide some temporary relief in individuals who present with stiffness It has been suggested that tricyclic antidepressants and selective serotonin reuptake inhibitors be used [8].

2.4 Nursing Management

Patients with Huntington's disease may be admitted to the hospital for problems linked to the disease and developed a plan of care according to the needs of the patient and implement and evaluate the care.

1. **Safety:** Avoid injuries and potential skin breakdown. Clean the skin well, and stimulate ambulation to assist maintain muscle tone. While feeding, keep the patient as upright as feasible. While feeding, gently support the patient's head with one hand.
2. Medication regimen activities and possible adverse effects must be taught, evaluated, and modified to achieve the desired patient response.
3. **Family education:** The nurse must educate and assist the patient and family as they adjust to the necessary lifestyle adjustments, such as the illness worsens, patients and their families may require home care, case management, counselling, or even legal action to meet the patient's needs. In patients and their families, nurses should check for coping issues, neglect, or abuse. Educate them regarding moderate exercise on a regular basis can help to decrease tightness and spasms [9].



Scanned with CamScanner

Fig. 1. CT scan or MRI scans indicate symmetrical striatal atrophy

3. DISCUSSION

A 57-year-old man has been diagnosed with early-stage Huntington's disease. During the first visit, his relatives reported behavioral signs such as indifference as well as chorea in the distal upper extremities. Treatment designed to improve patient stated functional activities such as keyboard typing or blackboard writing (e.g., handwriting task) [10]. Because Huntington's disease is a progressive degenerative condition, therapies that may be useful to the patient in the future were also included in the interventions (e.g., aerobic exercise, respiratory muscle) [11]. The following therapies were conducted at the patient's initial visit: respiratory training, strength training, positioning and balance training, teaching on energy conservation during movement, and training on functional reach and grasp exercises. Balance and postural muscle training were initiated for the same reason: to improve functional mobility and minimize fatigue risks in anticipation of future respiratory muscle degradation. [12]. According to physicians, physiotherapy intervention in the early to middle stages of Huntington's disease can improve motor and functional performance and may even stop disease progression. As a consequence, implementing these treatments early in the disease will almost always assist the patient [13,14-23].

4. CONCLUSION

Huntington's disease is a chronic, hereditary nervous system ailment characterized by increasing uncontrollable choreiform movement. The disease affects around 1 in 10,000 men and women of all races in their forties. In this disease physiotherapy intervention may improve the patients self-efficacy, mindfulness and proper gait and balancing. The progressive nature of Huntington's disease demands multidisciplinary treatment and ongoing participation of care in order to provide the best possible assistance to the patient and their family.

CONSENT AND ETHICAL APPROVAL

The writers have acquired and saved patients' permission and ethical approval in accordance with international standards or university standard guidelines.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. *Eur J Neurol*. 2018;25(1):24-34. DOI:10.1111/ene.13413. PMID: 28817209.
2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*. 1993;72(6):971-83.
3. Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, et al. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. *Nat Genet*. 1994; 6(4):409-14.
4. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. *Nat Rev Dis Primer*. 2015;1: 15005.
5. Malkani P. A Clinical Review on Huntington Disease. *Glob J Pharm Pharm Sci* [Internet]. 2018 Nov 28 [cited 2021 Aug 30];6(4). Available:https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555693.php
6. Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. *Cold Spring Harb Perspect Med*. 2017;7(7):a024240.
7. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. *Nat Rev Dis Primers*. 2015;1:15005. DOI:10.1038/nrdp.2015.5.PMID: 27188817.
8. Frank S. Treatment of Huntington's Disease. *Neurotherapeutics*. 2014;11(1): 153-60.
9. Urrutia NL. Adult-onset Huntington disease: An update. *Nursing*. 2019 Jul;49(7):36-43. DOI: 10.1097/01.NURSE.0000559914.46449.29 . PMID: 31219985
10. Huntington disease: MedlinePlus Genetics [Internet]. [cited 2021 Aug 30]. Available:https://medlineplus.gov/genetics/condition/huntington-disease/
11. Huntington's Disease (HD) | Symptoms & Treatments | alz.org [Internet]. [cited 2021 Aug 30].

- Available:<https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/huntington-s-disease>
12. Chorea & Huntington's Disease [Internet]. [cited 2021 Aug 30]. Available:<https://www.movementdisorders.org/MDS/About/Movement-Disorder-Overviews/Chorea--Huntingtons-Disease.htm>
 13. Huntington's Disease: Genetics, Juvenile Cases & Chorea [Internet]. [cited 2021 Aug 30]. Available:<https://my.clevelandclinic.org/health/diseases/14369-huntingtons-disease>
 14. Yadav V, Naqvi WM, Burhani T. Pandemics and physiotherapy: An overview of the role of the physiotherapists in restoring functions and quality of life. *International Journal of Research in Pharmaceutical Sciences*. 2020b;11:1898–1901. Available:<https://doi.org/10.26452/ijrps.v11iSPL1.4550>
 15. Abbafati, C., Abbas, K.M., Abbasi-Kangevari, M.,2020b. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 396, 1223–1249. Available:[https://doi.org/10.1016/S0140-6736\(20\)30752-2](https://doi.org/10.1016/S0140-6736(20)30752-2)
 16. Abbafati, C., Machado, D.B., Cislighi, B.,2019 D., 2020d. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet* 396, 1160–1203. Available:[https://doi.org/10.1016/S0140-6736\(20\)30977-6](https://doi.org/10.1016/S0140-6736(20)30977-6)
 17. Dhande, R.P., Singhanian, A., Gupta, A., 2020. Role of diffusionweighted imaging in evaluation of intracranial infections. *Journal of Datta Meghe Institute of Medical Sciences University* 15, 26–29. Available:https://doi.org/10.4103/jdmimsu.jdmimsu_146_19
 18. Dwari, K., 2020. COVID-19 pandemic: A positive influence on lifestyle, economy, administration & environment; an overview. *Indian Journal of Forensic Medicine and Toxicology* 14, 6605–6610. Available:<https://doi.org/10.37506/ijfamt.v14i4.12646>
 19. Franklin, R.C., Peden, A.E., Hamilton, E.B.,2020. The burden of unintentional drowning: Global, regional and national estimates of mortality from the Global Burden of Disease 2017 Study. *Injury Prevention*. Available:<https://doi.org/10.1136/injuryprev-2019-043484>
 20. Gawande, V., Saoji, K., Nair, A., Saoji, K., 2020b. Radiological findings of spinal neurocysticercosis. *International Journal of Current Research and Review* 12, 164–168. Available:<https://doi.org/10.31782/IJCRR.2020.121824>
 21. Ghogare, A., Chowdhury, D., Patil, P., Vankar, G., 2020. Schizophrenia with obsessive-compulsive symptoms - Neuropsychiatric manifestation in the context of underlying brain pathology: A case report from rural tertiary health-care center from Maharashtra. *Journal of Datta Meghe Institute of Medical Sciences University* 15, 295–299. Available:https://doi.org/10.4103/jdmimsu.jdmimsu_34_20
 22. Kumar, S., Jain, S., Wanjari, A., Mandal, S., 2019a. Development and validation of a modified frailty risk index as a predictor of mortality in rural elderly people. *Asian Journal of Gerontology and Geriatrics* 14, 15–22. Available:<https://doi.org/10.12809/ajgg-2018-315-0a>
 23. Panchbudhe, S.A., Praveen Kumar, Y., Choudhary, S., Chiwhane, A., 2020c. Role of physiotherapist to promote physical activity in physical therapy settings: Questionnaire study. *International Journal of Current Research and Review* 12, 50–55. Available:<https://doi.org/10.31782/IJCRR.2020.5055>

© 2021 Meshram et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle4.com/review-history/74007>